CLAIMS

1. Use of a pharmaceutical composition in the manufacture of a medicament for reducing post operative complications of a human patient from injury based on a scheduled or anticipated surgical operation, wherein the pharmaceutical composition comprises a therapeutically effective amount of (i) an iron compound; and (ii) stannic protoporfin in a dose of 20–80 mg before the surgical operation, wherein the human patient is susceptible to photodermatoses.

2. The use of claim 1, wherein the stannic protoporfin is to be administered in a dose of 30–70 mg.

3. The use of claim 1, wherein the stannic protoporfin is to be administered in a dose of 45 mg.

4. The use of claim 1, wherein the iron compound is iron sucrose is to be administered at a dose of 190-290 mg.

5. The use of claim 1, wherein the iron compound is iron sucrose is to be administered at a dose of 240 mg.

6. The use of claim 1, wherein the stannic protoporfin is to be administered at a dose of 45 mg and iron compound is iron sucrose is to be administered at a dose of 240 mg.

7. The use of claim 1, wherein the human patient is to avoid sun exposure between the administration of the therapeutically effective composition and the scheduled or anticipated surgical operation, and wherein the human patient is to apply sunscreen when sunlight exposure is expected for at least 6 days after the scheduled or anticipated surgical operation.

8. The use of claim 1, wherein the human patient is to apply sunscreen when sun exposure is expected after the therapeutically effective composition is to be administered.

9. The use of claim 1, wherein the sunscreen has a sun protection factor (SPF) of 50+.

10. The use of claim 1, wherein the iron compound is present in an aqueous pharmaceutical composition comprising: iron sucrose; bicarbonate; and a pharmaceutically acceptable aqueous carrier.

11. The use of claim 1, wherein the stannic protoporfin is present in an aqueous pharmaceutical composition comprising: a total level of impurities of 1.5% or less, as measured by gas chromatography.

12. The use of claim 1, wherein preparing the therapeutically effective composition comprises combining in an intravenous bag:

a. an aqueous iron pharmaceutical composition comprising: iron sucrose; bicarbonate; and a pharmaceutically acceptable aqueous carrier; and

b. a stannic protoporfin composition having a total level of impurities of 1.5% or less, as measured by gas chromatography.

13. The use of claim 1, wherein the scheduled or anticipated surgical operation is organ transplant surgery.

14. The use of claim 1, wherein the pharmaceutical composition reduces or eliminates the need for a blood product to be administered after the scheduled or anticipated surgical operation.

15. The use of claim 1, wherein the blood products comprises whole blood from a donor.